United States· US:0009-3794_c8d8e348-2795-48de-9ac8-51ee0d0201af
Corvert
A ibutilide product containing ibutilide fumarate, registered in United States by Pharmacia & Upjohn Company LLC. The same ATC class is registered in 5 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Ibutilide is registered in 5 of 19 countries.
Countries holding a registration under ATC C01BD05 (ibutilide), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 3 of them publish a price we can compare per daily dose
Ibutilide · ATC C01BD05
5 / 19 countries
- Canada
- Finlandprice
- Netherlands
- Norwayprice
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- IBUTILIDE FUMARATE
- Manufacturer
- Pharmacia & Upjohn Company LLC
- Country
- United States (US)
- ATC code
- C01BD05
- ATC class
- Ibutilide
- Defined daily dose
- 1 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1100093794011 VIAL, SINGLE-DOSE in 1 CARTON (0009-3794-01) / 10 mL in 1 VIAL, SINGLE-DOSE
- ndc110009-3794-01
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
175 interactions on record for ibutilide.
Graded by severity as the source publishes them — 131 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ibutilide · interactions on record
175 records
- 131 severe
- 41 moderate
- 2 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ibutilide in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandCorvertOrifarm Oy
- CanadaCORVERTPFIZER CANADA ULC
- NetherlandsCorvert 87 µg/ml, oplossing voor intraveneuze infusiePfizer B.V.
- NorwayCorvertPfizer
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- Austria · Corvert
- Finland · Corvert
- Italy · Corvert
- Netherlands · Corvert
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/af8b9a9f-3302-4fd2-a33a-84c03ca1505f GET /v1/drugs/af8b9a9f-3302-4fd2-a33a-84c03ca1505f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": ".1",
"substance": "IBUTILIDE FUMARATE",
"productndc": "0009-3794",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "NDA020491",
"marketing_category": "NDA"
}See everything about ibutilide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.